Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Marek Malecki

Marek Malecki

Phoenix Biomolecular Engineering Foundation, USA

Title: Universal therapeutic vaccine against influenza

Biography

Biography: Marek Malecki

Abstract

The CDC reports 3697 deaths due to influenza in 2013. First line therapeutics recommended for the patients who are already suffering from influenza are systemic therapeutics: oseltamivir (oral), zanamivir (inhaled), peramivir (intravenous) for patients who present within first 48 hours from the initial symptoms and for people who are at the high risk of exposure. Additionally recommended are: amantadine and rimantadine. Meanwhile, the preventive vaccination of patients 6 months – 17 years of age reached only 49.9%. However, these measures promoted by the CDC are not meant for the general populations. Importantly, the main problem with these medications is that efficacy of prophylactic and therapeutic vaccinations is hindered by the quickly changing genotypes of new strains of viruses. This leads to resistance to therapies of the new strains. Furthermore, with the changing genotype, surface displayed molecular profiles may also change. The changed phenotypes lead to ineffective therapies or absence of immune responses. Moreover, the development of the immune response takes time. It takes approximately 5-7 days for the 1st round of antibody generation. The booster shot or prolonged / secondary exposure is needed to yield the amplified response in 45-55 days. The sick patients cannot wait that long. Last but not least, the aforementioned therapeutics may inflict very serious iatrogenic adverse effects. To address these problems, by computer modeling and statistical analysis, we have designed and bioengineered universal therapeutic vaccine for influenza as the solution. It is capable of mounting an immediate, amplified, and reliable response, while avoiding  entirely adverse effects reported by the currently recommended therapeutics.